Konica Minolta subsidiary Invicro is directing attention to new research results from its TauIQ software for quantitative analysis of tau PET biomarker data in Alzheimer's disease clinical trials. The company has also launched the software.
In a study published in the January issue of the Journal of Nuclear Medicine, researchers from Invicro detailed how TauIQ could quantify both local and global tau measures, yielding better results than standardized uptake value ratio-based methods.
TauIQ provides quantitative analysis of tau PET biomarker data in Alzheimer's disease. Image courtesy of Invicro.Invicro has launched TauIQ in its core lab as part of its IQ-Analytics platform, which includes the firm's AmyloidIQ and DaTIQ algorithms.
